These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35561299)

  • 41. Management of mantle cell lymphoma in the elderly: current and potential strategies.
    Vignon M; Venon MD; Hermine O; Delarue R
    Drugs Aging; 2013 Dec; 30(12):979-86. PubMed ID: 24178346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
    Wallace D; Reagan PM
    Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
    Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
    Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
    [No Abstract]   [Full Text] [Related]  

  • 45. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions.
    Diamond B; Kumar A
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):613-626. PubMed ID: 31229158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dismantling relapsed/refractory mantle cell lymphoma.
    Ryan CE; Kumar A
    Blood Rev; 2024 Jun; ():101221. PubMed ID: 38906740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
    N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK
    Curr Med Chem; 2023 Oct; ():. PubMed ID: 37818564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
    Tbakhi B; Reagan PM
    Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mantle Cell Lymphoma -  Cutting edge Dia-gnostics and Treatment Approaches].
    Klener P; Trněný M
    Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Unmet needs in the treatment of mantle cell lymphoma.
    Rosen ST; Link BK; Fowler NH
    Clin Adv Hematol Oncol; 2013 Nov; 11(11 Suppl 18):1-19. PubMed ID: 24893041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment strategies in mantle cell lymphoma.
    Maddocks K; Blum KA
    Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Jain P; Wang ML
    Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biology and therapy of mantle cell lymphoma.
    Williams ME; Densmore JJ
    Curr Opin Oncol; 2005 Sep; 17(5):425-31. PubMed ID: 16093790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular Therapies for Mantle Cell Lymphoma.
    Yassine F; Sandoval-Sus J; Ayala E; Chavez J; Hamadani M; Kharfan-Dabaja MA
    Transplant Cell Ther; 2021 May; 27(5):363-370. PubMed ID: 33965173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.